Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference

Core Insights - Oragenics, Inc. is participating in the 15th Annual Traumatic Brain Injury Conference to showcase advancements in intranasal therapies for concussion and brain-related conditions [1][2] Company Overview - Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, particularly its lead candidate ONP-002 for mild traumatic brain injury (mTBI) [6] - The company is advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration [6] Conference Participation - The Annual Traumatic Brain Injury Conference is hosted by Arrowhead Sci-Tech Conferences & Events, bringing together leaders from various sectors to discuss TBI research and clinical care [2] - Dr. W. Frank Peacock, Chief Clinical Officer of Oragenics, will present on "An Update on HeadSMART II: Advancing Precision Strategies for Traumatic Brain Injury Detection and Management" [3] Research and Collaboration - The HeadSMART II trial is one of the largest ongoing U.S. emergency department prospective biomarker discovery trials for mild traumatic brain injury, expected to enroll over 2,000 patients [4] - Findings from HeadSMART II may reshape the understanding of the mTBI population and influence future clinical trial enrollment strategies [4] - Oragenics is collaborating with BrainBox Solutions to create a comprehensive test-to-treat platform for mTBI, combining diagnostic technologies with its therapeutic candidate ONP-002 [5]